STAT

The Senate could soon pass an opioids package. But a new law is still a long way away

The House passed a big opioids bill, the Senate is about to vote on its own version — but a law? That’s a long way off.
A man walks by a billboard for a drug recovery center in Youngstown, Ohio.

WASHINGTON — The Senate is likely to pass a comprehensive bill to address the opioid crisis in the coming weeks. The House did so in June.

But the finish line on that long-discussed priority remains a long way off.

Lawmakers have left untouched many of the bill’s most contentious issues, like debates over patient privacy and expensive changes to Medicaid payments for addiction treatment. There’s no sign yet they’ll iron out those issues before the Senate votes.

That procrastination means a select group of lawmakers will spend September and October — if not longer — hammering out the contentious details. A final vote, lawmakers, congressional aides, and

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks